84
Participants
Start Date
December 19, 2024
Primary Completion Date
December 23, 2026
Study Completion Date
February 16, 2028
frexalimab
frexalimab treatment
brivekimig
brivekimig treatment
rilzabrutinib
rilzabrutinib treatment
placebo
placebo treatment
RECRUITING
Investigational Site Number : 3480001, Budapest
RECRUITING
Investigational Site Number : 0360003, Garran
RECRUITING
Investigational Site Number : 0360001, Parkville
RECRUITING
Investigational Site Number : 1580002, Taipei
RECRUITING
Investigational Site Number : 8400001, New York
RECRUITING
Investigational Site Number : 2760002, Berlin
RECRUITING
Investigational Site Number : 2030001, Prague
RECRUITING
Investigational Site Number : 7240002, Córdoba
RECRUITING
Investigational Site Number : 4840001, Mexico City
RECRUITING
Investigational Site Number : 3800001, Brescia
RECRUITING
Investigational Site Number : 8400021, Chapel Hill
RECRUITING
Investigational Site Number : 2760003, Hanover
RECRUITING
Investigational Site Number : 8400007, Birmingham
RECRUITING
Investigational Site Number : 7920002, Kayseri
RECRUITING
Investigational Site Number : 7240005, Seville
RECRUITING
Investigational Site Number : 7920001, Kocaeli
RECRUITING
Investigational Site Number : 7240003, Valencia
RECRUITING
Investigational Site Number : 8400010, Ann Arbor
RECRUITING
Investigational Site Number : 3800002, Florence
RECRUITING
Investigational Site Number : 8400019, Edina
RECRUITING
Investigational Site Number : 8400017, Hinsdale
RECRUITING
Investigational Site Number : 8400014, Chicago
RECRUITING
Investigational Site Number : 4840003, Monterrey
RECRUITING
Investigational Site Number : 2500001, Paris
RECRUITING
Investigational Site Number: 8400024, Dallas
RECRUITING
Investigational Site Number: 8400016, Houston
RECRUITING
Investigational Site Number : 2030002, Olomouc
RECRUITING
Investigational Site Number : 8400005, El Paso
RECRUITING
Investigational Site Number : 3800003, Naples
RECRUITING
Investigational Site Number: 8400018, Las Vegas
RECRUITING
Investigational Site Number : 8400015, Orange
RECRUITING
Investigational Site Number : 2500002, Créteil
RECRUITING
Investigational Site Number : 8400012, San Francisco
RECRUITING
Investigational Site Number : 7030003, Banská Bystrica
RECRUITING
Investigational Site Number : 1560001, Beijing
RECRUITING
Investigational Site Number : 1560004, Shanghai
RECRUITING
Investigational Site Number : 1580001, Taichung
RECRUITING
Investigational Site Number : 1560003, Chengdu
RECRUITING
Investigational Site Number : 1520003, Temuco
RECRUITING
Investigational Site Number : 1520002, Santiago
RECRUITING
Investigational Site Number : 0320001, CABA
RECRUITING
Investigational Site Number : 0320002, Córdoba
RECRUITING
Investigational Site Number : 0760002, São Paulo
RECRUITING
Investigational Site Number: 0760001, São Paulo
RECRUITING
Investigational Site Number : 1240002, London
RECRUITING
Investigational Site Number : 1240001, Montreal
RECRUITING
Investigational Site Number : 1240006, Québec
RECRUITING
Investigational Site Number : 3000002, Athens
RECRUITING
Investigational Site Number : 3000001, Heraklion Crete
RECRUITING
Investigational Site Number : 5280001, Amsterdam
RECRUITING
Investigational Site Number : 6160001, Lodz
RECRUITING
Investigational Site Number : 6160002, Opole
RECRUITING
Investigational Site Number : 6200001, Matosinhos Municipality
RECRUITING
Investigational Site Number : 6200002, Vila Nova Gaia
RECRUITING
Investigational Site Number : 7030004, Bratislava - Kramare
RECRUITING
Investigational Site Number : 7030001, Martin
RECRUITING
Investigational Site Number : 7240004, Barcelona
RECRUITING
Investigational Site Number : 7240001, Barcelona
RECRUITING
Investigational Site Number : 8260004, Salford
RECRUITING
Investigational Site Number : 8260005, Oxford
RECRUITING
Investigational Site Number : 8260001, Leicester
Lead Sponsor
Sanofi
INDUSTRY